share_log

Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial

Benzinga ·  Sep 11 01:31
  • Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
  • Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease
  • If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment